The concept of e-sports is being established as a sport that we have previously recognized, not just a simple electronic game. However, it is not clear whether e-sports share the same characteristics as sports, and even if they do, how doping will be a problem in e-sports. In this paper, we examined how to deal with the doping issue in e-sports by comparing the characteristics of general sports and e-sports. We also investigated what form doping will take in e-sports and what information pharmacists should know in the future. In conclusion, it is necessary to expand the scope of anti-doping activities that have been actively implemented in existingsports to the field of e-sports to prevent damage to the health of e-sports athletes and maintain fairness and transparency in e-sportsactivities. In addition, it is thought that pharmacists, who are experts in medication, will need to understand the overall characteristicsof e-sports and the differences in the target group at risk of doping and activate their role in providing individualized pharmaceuticalservices in the future.

The concept of e-sports is being established as a sport that we have previously recognized, not just a simple electronic game. However, it is not clear whether e-sports share the same characteristics as sports, and even if they do, how doping will be a problem in e-sports. In this paper, we examined how to deal with the doping issue in e-sports by comparing the characteristics of general sports and e-sports. We also investigated what form doping will take in e-sports and what information pharmacists should know in the future. In conclusion, it is necessary to expand the scope of anti-doping activities that have been actively implemented in existingsports to the field of e-sports to prevent damage to the health of e-sports athletes and maintain fairness and transparency in e-sportsactivities. In addition, it is thought that pharmacists, who are experts in medication, will need to understand the overall characteristicsof e-sports and the differences in the target group at risk of doping and activate their role in providing individualized pharmaceuticalservices in the future.

The concept of e-sports is being established as a sport that we have previously recognized, not just a simple electronic game. However, it is not clear whether e-sports share the same characteristics as sports, and even if they do, how doping will be a problem in e-sports. In this paper, we examined how to deal with the doping issue in e-sports by comparing the characteristics of general sports and e-sports. We also investigated what form doping will take in e-sports and what information pharmacists should know in the future. In conclusion, it is necessary to expand the scope of anti-doping activities that have been actively implemented in existingsports to the field of e-sports to prevent damage to the health of e-sports athletes and maintain fairness and transparency in e-sportsactivities. In addition, it is thought that pharmacists, who are experts in medication, will need to understand the overall characteristicsof e-sports and the differences in the target group at risk of doping and activate their role in providing individualized pharmaceuticalservices in the future.

The concept of e-sports is being established as a sport that we have previously recognized, not just a simple electronic game. However, it is not clear whether e-sports share the same characteristics as sports, and even if they do, how doping will be a problem in e-sports. In this paper, we examined how to deal with the doping issue in e-sports by comparing the characteristics of general sports and e-sports. We also investigated what form doping will take in e-sports and what information pharmacists should know in the future. In conclusion, it is necessary to expand the scope of anti-doping activities that have been actively implemented in existingsports to the field of e-sports to prevent damage to the health of e-sports athletes and maintain fairness and transparency in e-sportsactivities. In addition, it is thought that pharmacists, who are experts in medication, will need to understand the overall characteristicsof e-sports and the differences in the target group at risk of doping and activate their role in providing individualized pharmaceuticalservices in the future.

Background: It was to describe collaborative educational efforts under Coronavirus disease 2019 period to advocate pharmacybased immunization delivery and meet unmet needs of partnership institution using virtual learning platforms. Methods: A partnership was established among three pharmacy schools from two countries. The class content included the history of pharmacy immunization, pharmacists’ roles and contribution to public health of the USA. The class also reviewed the value of pharmacists as frontline healthcare workers to foster student insights and the scope of pharmacy. The virtual class featured an interactive video simulation and small breakroom discussion besides a lecture. Results: Participants indicated that public accessibility to pharmacy and six-year education system in South Korea as advantages. However, legislative restrictions, pharmacist burden, and interprofessional disagreements were expressed as barriers to introduce the pharmacist immunization. Conclusion A virtual learning platform was used to advocate for pharmacy-based immunization and fulfilled an unmet educational gap at a partnership institution.

The World Anti-Doping Agency has made efforts to promote the safe use of medications and prevent doping in sports globally. International standards have been established and experts have advocate anti-doping education to athletes and healthcare professionals. Pharmacists are expected to participate in the pharmaceutical care activity of sports medicine in protecting the athletes while providing the spirits of clean sports. In this review, we described the pharmacists’ roles and functions in six areas of sports pharmaceutical care: awareness, treatment, prevention, optimization, abuse, and monitoring. Sports pharmacists should be able to prevent inappropriate drug use and manage athletes’ illness and injury using pharmacotherapy. Further pharmacists should actively involve to educate and counsel athletes, trainers, and healthcare teams. In conclusion, pharmacists are expected to play important roles in sports pharmacy, which is the emerging area of specialized pharmaceutical care services.

The World Anti-Doping Agency has made efforts to promote the safe use of medications and prevent doping in sports globally. International standards have been established and experts have advocate anti-doping education to athletes and healthcare professionals. Pharmacists are expected to participate in the pharmaceutical care activity of sports medicine in protecting the athletes while providing the spirits of clean sports. In this review, we described the pharmacists’ roles and functions in six areas of sports pharmaceutical care: awareness, treatment, prevention, optimization, abuse, and monitoring. Sports pharmacists should be able to prevent inappropriate drug use and manage athletes’ illness and injury using pharmacotherapy. Further pharmacists should actively involve to educate and counsel athletes, trainers, and healthcare teams. In conclusion, pharmacists are expected to play important roles in sports pharmacy, which is the emerging area of specialized pharmaceutical care services.

Objective: The rising number of carbapenemase-resistant Enterobacteriaceae (CRE) cases has become a concern worldwidely. This study investigated patient characteristics with CRE and analyzed the risk factors associated with its acquisition. Methods: A retrospective review of the electronic medical records of the Kangbuk Samsung Medical Center from May 2016 to April 2019 was performed. The inclusion criterion was hospitalized patients aged ≥18 years with confirmed CRE acquisition. Patients were divided by CRE acquired and non-required patients. CRE acquired patients were those with CRE confirmed by their active surveillance cultures, while non-acquired patients were those with carbapenemase-sensitive Enterobacteriaceae (CSE). If CRE was isolated more than once during hospitalization, only the first isolation was used for data analysis. Patient characteristics, antibiotic used, and the duration of use were compared between two groups using univariate analysis, and the risk factors associated with CRE were analyzed using multiple logistic regression analysis. Results: Among the 73 CRE acquired patients, 44 (60.3%) were positive for carbapenemase-producing Enterobacteriaceae (CPE). Infection from Klebsiella pneumonia (42 cases, 57.5%), Escherichia coli (17 cases, 23.3%), and Enterobacter cloacae (5 cases, 6.8%). The risk of CRE acquisition was significantly increased by 4.99 times [confidence interval (CI), 1.40-17.78; p=0.013] with mechanical ventilation, 3.86 times (CI, 1.59-9.36; p=0.003) with penicillin administration, and 21.19 times (CI, 6.53-68.70; p<0.001) with carbapenem administration. Conclusions Proper antibiotic use including the selection, frequency, and duration, and patients on mechanical ventilators need close monitoring.

OBJECTIVE: The purpose of the study was to investigate the time from the injection of muscle relaxants to the first spontaneous respiration between sugammadex and conventional reversal for patients undergoing laparoscopic cholecystectomy. METHODS: This study was retrospectively conducted on patients who were diagnosed with gallbladder stone (N802) between January 2014 and April 2017. The data were collected from the electronic medical records of a total of 186 patients (84 patients in the neostigmine group and 102 patients in the sugammadex group). RESULTS: The time required for the first spontaneous respiration in the sugammadex group was shorter than that in the neostigmine group (3.6 min vs 4.9 min; p < 0.05). After the injection of intermediate muscle relaxants, the comparison of heart rate and mean arterial pressure in the sugammadex and neostigmine groups revealed that the heart rate in the neostigmine group was higher than in the sugammadex group after 5 min (p < 0.05). The mean arterial pressure in the neostigmine group was higher than in the sugammadex group after 10 min (p < 0.05). A significant adverse effect of tachycardia was observed in the neostigmine group (p < 0.05), but the frequency of rescue antiemetic in the sugammadex group was significantly higher than in the neostigmine group (p < 0.05). CONCLUSION: In this study, the unwanted effect of neostigmine group was tachycardia; therefore, in the case of patients with hemodynamic instability, sugammadex is recommended. At 12 hours after the injection of sugammadex to patients, more antiemetics were required than in the neostigmine group; therefore, more research should be conducted on postoperative nausea and vomiting.
Antiemetics ; Arterial Pressure ; Cholecystectomy, Laparoscopic* ; Electronic Health Records ; Gallbladder ; Heart Rate ; Hemodynamics ; Humans ; Neostigmine* ; Postoperative Nausea and Vomiting ; Respiration* ; Retrospective Studies ; Tachycardia

BACKGROUND: We strived to evaluate the status of nivolumab use and associated factors on the clinical efficacy of the drug. METHODS: The study was retrospectively conducted in patients who had been administered nivolumab at least once at the cancer center of Seoul National University Hospital from June 2015 to April 2017. Data were collected from electronic medical records. A medication-use evaluation was performed based on the American Society of Health-System Pharmacists mediation-use guidelines. RESULTS: Sixty-six of the 74 patients (89.2%) showed indications approved for nivolumab use by the Korean Ministry of Food and Drug Safety (MFDS; n=55) or the US Food and Drug Administration (FDA; n=11). Approximately 73.0% of the patients were administered the approved dose of 3 mg/kg but 25.7% were administered an unapproved fixed dose of 100 mg. The overall response rate was 21.7%, and the response rate of non-small cell lung cancer patients, who accounted for the largest number of indications, was 18.8%. Adverse reactions were found in 90.1% of the patients and were mostly mild (86%). The expression of programmed death-ligand 1 (PD-L1) was analyzed as a factor affecting treatment response (p=0.028, odds ratio [OR]=11.331). CONCLUSION: PD-L1 expression was found to affect treatment response. However, caution is required while using an unapproved dosage and in the absence of monitoring for effectiveness and safety. Therefore, an effective protocol or instruction manual for the proper use of nivolumab should be considered.
Carcinoma, Non-Small-Cell Lung ; Electronic Health Records ; Hospitals, General* ; Humans ; Odds Ratio ; Pharmacists ; Retrospective Studies ; Seoul ; Treatment Outcome ; United States Food and Drug Administration